Related Experiment Videos

PPARgamma-independent antitumor effects of thiazolidinediones

Shuo Wei1, Jian Yang, Su-Lin Lee

  • 1Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Parks Hall, The Ohio State University, 500 West 12th Avenue, Columbus, OH 43210, USA.

Cancer Letters
|September 16, 2008
PubMed

Insights

Thiazolidinediones (TZDs) show anticancer effects through PPARgamma-independent pathways. These drugs target cancer cell survival mechanisms, offering potential for new cancer therapies.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Thiazolidinediones (TZDs), known PPARgamma agonists, exhibit anticancer properties.
  • Emerging evidence suggests TZDs exert antitumor effects via mechanisms independent of PPARgamma activation.
  • These off-target effects influence critical cellular processes like cell cycle progression and survival in cancer cells.

Purpose of the Study:

  • To review the "off-target" mechanisms responsible for the antitumor effects of TZDs.
  • To highlight key pathways involved in TZD-mediated cancer cell death and growth inhibition.
  • To explore the translational potential of TZDs as anticancer agents.

Main Methods:

  • Review of existing literature on TZD mechanisms of action.
  • Focus on three primary "off-target" pathways: Bcl-2/Bcl-xL inhibition, proteasomal degradation of regulatory proteins, and androgen receptor (AR) repression.
  • Analysis of differential effects on malignant versus nonmalignant cells.

Main Results:

  • TZDs induce cell cycle arrest, differentiation, and apoptosis in cancer cells through PPARgamma-independent pathways.
  • Key mechanisms include inhibition of Bcl-2/Bcl-xL, proteasomal degradation of cell cycle/apoptosis proteins, and Sp1-mediated AR transcriptional repression.
  • Nonmalignant cells show resistance to these specific antitumor effects.

Conclusions:

  • PPARgamma-independent mechanisms of TZDs contribute significantly to their anticancer activity.
  • The differential sensitivity between tumor and nonmalignant cells suggests therapeutic potential.
  • TZDs can serve as scaffolds for developing novel anticancer agents with unique mechanisms of action.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...